Histology Technician 2

Veracyte acquires Convergent Genomics, expanding its Urology diagnostics portfolio with a urinary tumor DNA testing platform. Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey. September 14, 2026 16:05 ET | Source: Veracyte, Inc. SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) - Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced its acquisition of Convergent Genomics. The acquisition adds Convergent Genomics' UroAmp platform, including its proprietary urinary tumor DNA (utDNA) technology, to Veracyte's product portfolio. To date, UroAmp has been clinically validated in non-muscle invasive bladder cancer (NMIBC), including therapy-response monitoring and post-treatment surveillance. In the U.S., there are approximately 85,000 patients diagnosed with bladder cancer annually, including about 65,000 with NMIBC. Of the 750,000 patients living with bladder cancer, approximately 600,000 are living with NMIBC. NMIBC is generally confined to the bladder and may shed only limited tumor DNA into the bloodstream, which can make blood-based detection challenging. Urine, by contrast, comes into direct contact and can provide a highly relevant source of tumor-derived genomic information. UroAmp analyzes this information, creating the potential to help inform treatment decisions and monitor patients throughout their care. "Bladder cancer care is advancing quickly, yet clinicians and patients still face significant uncertainty at critical decision points," said Marc Stapley, Veracyte's chief executive officer. "UroAmp brings a differentiated urine-based platform that is especially well suited to non-muscle-invasive disease. Together with our Decipher Bladder and TrueMRD tests, this acquisition strengthens Veracyte's ability to deliver complementary insights from urine, tissue, and blood to help guide care across the bladder cancer continuum." UroAmp is supported by a robust and growing body of evidence, including nine peer-reviewed publications and more than 40 posters and abstracts. Veracyte's initial test will be intended to help determine whether patients who have completed Bacillus Calmette-Guerin (BCG) induction therapy are likely to benefit from maintenance treatment. The company expects to commercialize this test in late 2028, subject to reimbursement timelines. Veracyte also plans to expand its use of the UroAmp platform to additional indications, including intravesical maintenance therapy monitoring and surveillance following treatment with curative intent. In the RUMBLE study published in The Journal of Urology, a multicenter prospective clinical validation study, patients who were clinically negative following induction BCG treatment but tested positive for utDNA had a 12-month recurrence-free survival rate of 25%, compared with 91% among utDNA-negative patients.[1] "This acquisition brings together UroAmp's differentiated platform and scientific expertise with Veracyte's evidence-generation capabilities, commercial infrastructure, and established relationships," said Brian Slingerland, chief executive officer, Convergent Genomics. "We believe this combination can help accelerate the development of new tools that give physicians greater confidence in treatment and monitoring decisions and can ultimately improve care for people living with bladder cancer." The acquisition includes $150 million in upfront cash consideration and up to $30 million in additional cash consideration tied to key milestones related to UroAmp reimbursement efforts. Veracyte contemplated the ongoing operating expenses of Convergent in its previously provided 2026 adjusted EBITDA guidance and is not updating such guidance at this time. About Convergent Genomics Convergent Genomics was founded in 2015 by Trevor Levin, PhD, chief scientific officer, and a team of cancer biologists, urologic oncologists, and data scientists, in partnership with Oregon Health & Science University (OHSU) and Illumina Accelerator. The company has received multiple peer-review grants from the National Cancer Institute and is engaged in research with over 30 sites worldwide, including leading academic centers. Convergent Genomics operates its clinical laboratory in South San Francisco that is certified by the California Department of Public Health and nationally by CLIA-CMS. For more information visit www.convergentgenomics.com. About Veracyte Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company's molecular tests assess the unique biology of each patient's tumor to help clinicians answer essential questions about cancer care. Veracyte's Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company's portfolio includes the Afirma(R) Genomic Sequencing Classifier test, Decipher(R) Bladder Genomic Classifier test, Decipher(R) Prostate Genomic Classifier test, Prosigna(R) Breast Risk of Recurrence test, and the TrueMRD(TM) Monitoring Test for MIBC. For more information, visit Veracyte's website or follow the company on LinkedIn or X (Twitter). Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements, including statements regarding the anticipated short and long term strategic, clinical, commercial and financial benefits of the acquisition; the expected impact of the acquisition on Veracyte's near-term financial outlook; development, launch, commercialization, reimbursement and timing of tests based on the acquired technology, including UroAmp; the anticipated timing of launch of the first product; estimated market opportunities; potential commercial synergies; potential applications of UroAmp in other urological diseases; and ability to achieve anticipated milestones. Forward-looking statements can be identified by words such as "anticipate," "believe," "expect," "intend," "may," "plan," "potential," "will," "could" and similar expressions. Actual results may differ materially due to risks and uncertainties, including Veracyte's ability to integrate Convergent, retain key employees, achieve anticipated benefits of the acquisition, meet development timelines, demonstrate clinical validity and utility of acquired products, obtain reimbursement for acquired products and commercialize new tests, including UroAmp. Additional factors are described under "Risk Factors" in Veracyte's most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. These statements speak only as of the date of this release, and Veracyte disclaims any obligation to update them except as required by law. Investors: Kelly Gura [email protected] [1] Bahlburg H, Maas M, Contreras-Sanz A, et al. Urine tumor DNA testing identifies recurrence and monitors therapy response in patients with high-risk non-muscle-invasive bladder cancer receiving intravesical bacillus Calmette-Guérin. J Urol. 2026;216(3):388-399. doi:10.1097/JU.0000000000005130.

Veracyte reported second-quarter profit of $25.5 million, with adjusted earnings of 54 cents per share, surpassing Wall Street's expectations of 43 cents per share. The South San Francisco-based molecular diagnostic company posted revenue of $150.3 million, exceeding analysts' forecasts of $144.4 million. The company projects full-year revenue between $590 million and $596 million. The results beat estimates from three analysts surveyed by Zacks Investment Research across both earnings and revenue metrics.

Veracyte Q2 earnings call highlights. July 31, 2026 Key points. * Veracyte reported strong Q2 results, with revenue up 15% to $150.3 million, testing revenue up 19% to $145.7 million, and adjusted EBITDA of $44 million. The company generated $45.8 million in operating cash flow and ended the quarter with $485.2 million in cash and short-term investments. * The company raised its 2026 revenue outlook to $590 million-$596 million, representing 14%-15% growth, while maintaining its expectation for an adjusted EBITDA margin above 26%. * Veracyte launched its Prosigna breast cancer test and TrueMRD bladder cancer recurrence-monitoring test; neither is included in current 2026 guidance. Core products also performed well, with Decipher Prostate revenue up 20% and Afirma revenue up 18%. * MarketBeat previews the top five stocks to own by August 1st. Veracyte NASDAQ: VCYT reported second-quarter 2026 revenue growth of 15% and raised its full-year revenue outlook, while highlighting the launches of its Prosigna LDT breast cancer test and TrueMRD recurrence-monitoring test for muscle-invasive bladder cancer. Chief Executive Officer Marc Stapley called the quarter a milestone for the company, saying the new products expand Veracyte's portfolio across the cancer-care continuum. The company also said it is approaching the milestone of serving its one millionth patient. Total revenue was $150.3 million, up 15% from the prior-year period, while testing revenue increased 19% to $145.7 million, Chief Financial Officer Rebecca Chambers said. Total test volume rose 13% to about 51,000 tests, and testing volume increased 14% to 48,389 tests. Veracyte generated $45.8 million in cash from operations during the quarter and ended the period with $485.2 million in cash equivalents and short-term investments. GAAP net income was $25.5 million, while adjusted EBITDA totaled $44 million, or 29.2% of revenue. Revenue guidance raised. The company raised its 2026 total revenue guidance to a range of $590 million to $596 million, representing projected growth of 14% to 15%. Its prior outlook called for $582 million to $592 million in revenue. Testing revenue is now expected to be between $576 million and $582 million, representing growth of 17% to 18%. The forecast includes about $10 million in other testing revenue from cytology services and Decipher Bladder. Chambers said the company continues to expect adjusted EBITDA margin of more than 26% for the year, despite investments behind growth initiatives. She said the higher revenue outlook reflects stronger-than-expected average selling prices and prior-period collections, or PPCs. * Testing average selling price was $3,010, up 4% year over year and including about $4.5 million in PPCs. * Normalized testing ASP, excluding PPCs, increased 3% to about $2,900. * Non-GAAP gross margin rose 340 basis points to 74.9%. * Testing gross margin rose 200 basis points to 76%, supported by workflow efficiencies, higher ASP and PPCs. Chambers said the company expects ASP to be slightly higher in 2026 than in 2025. However, she noted that Prosigna's launch and reimbursement status could create a modest gross-margin headwind in the second half. Prosigna and TrueMRD launches. Veracyte launched its Prosigna LDT in the United States following presentation of results from the OPTIMA trial at the American Society of Clinical Oncology meeting. Prosigna is designed to help guide treatment decisions for patients with estrogen receptor-positive, HER2-negative breast cancer by assessing recurrence risk over 10 years and likelihood of chemotherapy benefit. Discover more MarketBeat All Access MarketBeat Portfolio Tools Stapley said the independent prospective Phase III OPTIMA trial enrolled more than 4,400 high-risk, early-stage breast cancer patients and met its primary endpoint. According to the company, the study showed that more than two-thirds of clinically high-risk patients may be able to avoid chemotherapy without compromising outcomes, including premenopausal women and patients with up to nine positive lymph nodes. The company said it is engaged with more than 100 institutions, including academic cancer centers, integrated health systems and regional oncology networks, regarding Prosigna adoption. Stapley said some organizations are evaluating use of the test across their breast cancer programs. During the question-and-answer session, Chief Commercial Officer John Leite said Prosigna has Medicare coverage through the company's existing FDA-approved product. Veracyte is seeking a technical assessment for the centralized LDT version from MolDX, followed by pricing discussions. Leite said the company previously guided to pricing at the low end of about $2,500. The company is expanding its sales force earlier than originally planned in response to demand and is investing in electronic health record integration. Chambers said Veracyte expects to expand the Prosigna sales force from roughly 10 people to 15 by year-end. The company's 2026 guidance does not include revenue from Prosigna or TrueMRD. Veracyte also launched TrueMRD for recurrence monitoring in muscle-invasive bladder cancer patients following radical cystectomy. The test secured Medicare reimbursement and is the company's first commercial product on its minimal residual disease platform. Stapley said TrueMRD uses whole-genome sequencing for both the initial landmark test and subsequent surveillance testing. Core franchise performance. Decipher Prostate revenue increased 20% year over year, driven primarily by 17% volume growth and improved ASP, Stapley said. The company processed just under 30,000 Decipher Prostate tests during the quarter. Veracyte reduced its full-year Decipher volume expectation by approximately 1%, or slightly more than 1,000 tests, primarily due to lower expectations in low-risk disease. Stapley said most of that shortfall occurred during the second quarter and reflected changes to guidelines affecting active-surveillance testing rather than a loss of market share. Management said Decipher's intermediate- and high-risk prostate cancer segments continue to show strong growth, supported by clinical evidence and guideline positioning. The company expects about 31,000 Decipher tests in the third quarter and 33,000 in the fourth quarter, while maintaining its expectation for roughly 20% Decipher revenue growth for the full year. Afirma delivered approximately 18,600 tests, representing 10% volume growth, while revenue rose 18%. The company attributed the performance to greater use among existing physicians, expansion of its ordering base, market-share gains, improved reimbursement and the V2 transcriptome workflow. Stapley said the workflow reduced Afirma's no-result rate and contributed approximately 400 basis points of volume growth during the quarter. Veracyte raised its full-year Afirma revenue growth outlook to approximately 12% to 14%, including an anticipated no-result-rate benefit of about 3% for the year. Looking ahead, management said it plans to continue investing in evidence generation, product development, commercial execution and operational infrastructure. Stapley said the company sees opportunities for longer-term growth across Prosigna, TrueMRD, Decipher, Afirma and bladder cancer diagnostics. About Veracyte (NASDAQ:VCYT). Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte's proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes. The company's flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Veracyte, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veracyte wasn't on the list. While Veracyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.